Marché mondial du traitement du carcinome à cellules de Merkel – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché du traitement du carcinome à cellules de Merkel

Le marché du traitement du carcinome à cellules de Merkel devrait connaître une croissance significative au cours de la période de prévision. Après le mélanome, le carcinome à cellules de Merkel est la deuxième cause la plus répandue de décès par cancer de la peau. Ce cancer est causé par un système immunitaire affaibli et une exposition extrême au soleil. Une forte adoption de l'immunothérapie et un remboursement favorable sont des indicateurs encourageants de la croissance du traitement du carcinome à cellules de Merkel. L'amélioration constante des infrastructures de santé et l'augmentation des revenus disponibles des personnes dans la région Asie-Pacifique devraient faire augmenter le marché au cours de la période de prévision. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

Data Bridge Market Research analyse le taux de croissance du marché du traitement du carcinome à cellules de Merkel au cours de la période de prévision 2022-2029. Le TCAC attendu du marché du traitement du carcinome à cellules de Merkel a tendance à être d'environ 3,87 % au cours de la période de prévision mentionnée. Le marché était évalué à 3,24 milliards USD en 2021 et devrait atteindre 4,39 milliards USD d'ici 2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du traitement du carcinome à cellules de Merkel

Market Definition

Merkel cell carcinoma treatment is also known as neuroendocrine carcinoma of the skin a rare and aggressive type of skin cancer that originates from the top layers of the skin. It is caused either by continued exposure to sun, weak immunity or maybe others idiopathic reasons. Weak immune systems and sun exposure encourage the effects of merkel cell carcinoma. MCC generally appears as a single painless lump when exposed to the sun. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Merkel Cell Carcinoma Treatment Market Dynamics

Drivers

• Increased Research Activities

Increasing research and development activities for the treatment of merkel cell carcinoma is projected to boost the market. In May 2017, researchers of Fred Hutchison University and the University of Washington in Seattle stated the results of a small study combining Avelumab with two other treatments. The combination therapy helps to improve the T cells generation and attacks the MCC cells. The National Cancer Institute has also began a clinical trial that involves the investigational study of the drug ipilimumab Merkel cell carcinoma. This boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global merkel cell carcinoma treatment market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased and Innovative Diagnostic Tools

Numerous tests and procedures can be performed to examine the skin to detect and diagnose carcinoma cells; however, certain factors of prognosis and treatment options decline the chances of recovery. Several new developments in skin biopsy approaches enable the diagnosis of diseases or infection at the cellular and molecular level, making way for early diagnosis and treatment of diseases.

• High-end Conduction of Clinical Trials

The merkel cell carcinoma pipeline is projected to boost the market. For instance, in December 2018, Merck Sharp & Dohme Corp., a Merck & Co., Inc. subsidiary, undertook a phase 3 open-label, single-arm study to assess the efficacy of pembrolizumab as first-line therapy in the candidates suffering from advanced merkel cell carcinoma. Also, in December 2018, Incyte Corporation undertook a phase 2 study of INCMGA00012 in candidates with metastatic Merkel cell carcinoma. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global merkel cell carcinoma treatment market over a forecast period.

• Side-effects of Varied Treatments

There are several side-effects associated with merkel cell carcinoma treatment that hamper the growth of the market. Side-effects of external radiation therapy include skin changes, diarrhoea, painful sores in the throat and mouth, nausea, fatigue, and dry mouth or thick saliva. The side-effects of the radiation thaerapy are temporary; however, some rare serious side-effects could become permanent. In a few cases, radiation to the chest could even cause lung damage, which may lead to breathing issues and shortness of breath.

This global merkel cell carcinoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global merkel cell carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Merkel Cell Carcinoma Treatment Market

The present Covid-19 pandemic has had a significant effect on all enterprises. The lack of beds to accommodate the needs of the growing number of patients was causing a medical aid shortage in the healthcare sector. The majority of enterprises are at a standstill, and those operating close to people's homes are barely able to handle revenue, which is causing the global economy to fluctuate. A major effect of the COVID-19 pandemic has been a delay in the treatment of intestine cancer, which can have harmful consequences for the overall and disease-free survival of patients. With the decline in COVID-19 cases, the number of referrals for intestine cancer treatment has reduced significantly.

Global Merkel Cell Carcinoma Treatment Market Scope

The global merkel cell carcinoma treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Immunotherapy
• Chemotherapy
• Others

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Merkel Cell Carcinoma Treatment Market Regional Analysis/Insights

The global merkel cell carcinoma treatment market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global merkel cell carcinoma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the rise cases of skin cancer and favourable government policies, and advanced healthcare facilities.

Asia-Pacific dominates the market due to the increase government initiatives and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Merkel Cell Carcinoma Treatment Market Share Analysis

The global merkel cell carcinoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global merkel cell carcinoma treatment market.

Key players operating in the global merkel cell carcinoma treatment market include:

• Johnson & Johnson Private Limited (États-Unis)
• Cipla Inc. (États-Unis)
• Abbott (États-Unis)
• AbbVie Inc. (États-Unis)
• Merck KGaA (Allemagne)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Amneal Pharmaceuticals LLC. (États-Unis)
• Pfizer Inc (États-Unis)
• Mylan NV (États-Unis)
• Novartis SA (Suisse)
• Société Bristol-Myers Squibb (États-Unis)
• GSK plc. (Royaume-Uni)
• Bayer AG (Allemagne)
• ImmunityBio, Inc (États-Unis)
• Oncovir, Inc (États-Unis)

SKU-54138